YM BioSciences and Oncoscience Report Response Rate of 35.3% in Pediatric Glioma

Oncoscience | March 1st, 2005

TheraCIM h-R3 (nimotuzumab) Phase II Results Presented at European High Grade Glioma Conference MISSISSAUGA, ON, Feb. 2...